Oncometabolites and The Heart
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Release Date: 02/21/2024
Coach & Conquer Hypertension with Team-Based Care
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A landmark study in the New England Journal of Medicine shows that hypertension control is no longer just about prescribing medications—it’s about systems, teams, and sustained engagement. 🩺📊 In a cluster-randomized trial across underserved populations, a multifaceted, team-based strategy—combining protocol-driven care, health coaching, and home BP monitoring—achieved a significant additional reduction of −6.4 mm Hg in systolic BP (P<0.001) and improved adherence. The message is clear: 👉 Evidence works—but only when implemented well 👉 Teams outperform...
info_outline
Hormones. Vessels. Clots 🧬
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk. Three takeaways: • Formulation matters • First year matters • Patient factors matter #Cardiology #Thrombosis #PrecisionMedicine #HormoneTherapy
info_outline
From Regurgitation to Restoration: 🔄 The TTVR Revolution Redefines Tricuspid Therapy
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A landmark study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence 🫀 ✅ 98.4% procedural success ✅ Near-complete TR elimination (97.7% at 30 days) ✅ Significant improvement in symptoms & quality of life ⚠️ Trade-off: ~16% new pacemaker rate in device-naïve patients In an elderly, high-risk cohort, TTVR delivers what surgery often cannot—restoration without incision, relief without delay. A meaningful step forward in structural heart disease—where the right heart finally takes center stage ✨
info_outline
Stroke. Safety. Strategy: The Factor XIa Revolution 🚀🧠
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A quiet shift, yet a profound one. 🧠 The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy. For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️ The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed? This study suggests we can. #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation...
info_outline
Seeds. Signals. Sanctuary: The Biology of Brain Metastases 🧠
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧠 Brain metastases remain a clinical frontier—common, complex, and still lethal. In Science Signaling, Chafe et al. unpack the biology: Blood Brain Barrier traversal, metabolic rewiring, and immune evasion. Key insight: metastasis is not just spread—it is adaptation. From adenosine-driven immunosuppression to neuronal-like tumor states, new therapeutic doors are opening. Precision oncology must now think beyond the primary tumor. #BrainMetastases #Oncology #NeuroOncology #Immunotherapy #PrecisionMedicine
info_outline
Great Doctors Series: 🎙️ Sushruta: Scalpel. Science. Soul 🩺✨
Dr. RR Baliga's 'Podkast for the Kurious Doc'
What if the roots of modern surgery were written over 2,000 years ago? 🩺📜 Meet —a pioneer whose Suśruta Saṃhitā laid the foundations of plastic surgery, cataract procedures, and structured medical training. From rhinoplasty to hands-on simulation using natural models, his approach was remarkably ahead of its time. A reminder that innovation is often rediscovery—and that the future of medicine is deeply anchored in its past. 🌍✨ #HistoryOfMedicine #Ayurveda #Surgery #MedicalEducation #Innovation
info_outline
Stop. Test. Rethink: The Thyroxine Turning Point 🔄🧠💊
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧠💊 Stop. Test. Rethink. A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine, maintaining normal thyroid function—especially those on low doses (≤50 μg/day). 📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment The message is elegant: Not every prescription deserves permanence. Time to reassess, deprescribe, and individualize—particularly in our older patients. #Thyroid #Endocrinology #Deprescribing #Geriatrics...
info_outline
Reversing Heart Failure: Where immunology meets cardiology
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating step forward in Nature—where immunology meets cardiology. 🧬❤️ This study shows that engineered dendritic cells can locally reprogram the immune response, reduce fibrosis, and improve cardiac function—without systemic immunosuppression. The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic. From FAP-targeted delivery to checkpoint-mediated tolerance (PD-L1, CTLA4-Ig, IL-10), this work opens the door to a new therapeutic paradigm—precision immunotherapy for heart failure. 🚀 The seeds of...
info_outline
Chronology vs Physiology: A Clinical Reckoning ⚖️❤️🩹
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧠⏳ Age. Biology. Truth. A compelling Perspective in the New England Journal of Medicine challenges one of medicine’s quiet assumptions: that age equals risk. Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making ⚠️ The consequence? Missed prevention in the young, withheld therapy in the old. ✨ The opportunity? A shift toward biologically grounded, precision care—where treatment aligns not with years lived,...
info_outline
The Genetics of GLP-1 Response 🧬💊📊
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉 A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects. 📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics The future may not be “one drug fits all,” but one genome, one strategy.
info_outlineOncometabolites and The Heart
Dr RR Baliga 'Got Knowledge Doc' PodKasts for Cardio-Oncologists
Baliga RR, Young JB. Energizing Diastole Heart Fail Clin. 2008;4(1):ix‐xiii.
Sulkowski, P.L., Oeck, S., Dow, J. et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature (2020).
Taegtmeyer H, et al Oncometabolic Tracks in the Heart. Circ Res. 2017